GAMIMUNE Drug Profile

Summary for Tradename: GAMIMUNE

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for GAMIMUNE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for GAMIMUNE Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for GAMIMUNE Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Grifols Therapeutics Llc	GAMIMUNE	immune globulin intravenous (human)	Injection	101147		2036-12-20	Patent claims search
Grifols Therapeutics Llc	GAMIMUNE	immune globulin intravenous (human)	Injection	101147		2038-12-19	Patent claims search
Grifols Therapeutics Llc	GAMIMUNE	immune globulin intravenous (human)	Injection	101147		2038-07-09	Patent claims search
Grifols Therapeutics Llc	GAMIMUNE	immune globulin intravenous (human)	Injection	101147		2030-12-07	Patent claims search
Grifols Therapeutics Llc	GAMIMUNE	immune globulin intravenous (human)	Injection	101147		2034-03-11	Patent claims search
Grifols Therapeutics Llc	GAMIMUNE	immune globulin intravenous (human)	Injection	101147		2034-02-28	Patent claims search

Market Dynamics and Financial Trajectory for GAMIMUNE

Last updated: April 16, 2026

What is GAMIMUNE?

GAMIMUNE is a marketed human immunoglobulin (IgG) product used primarily for primary immunodeficiency (PID), secondary immunodeficiency, and autoimmune conditions. It is produced from pooled plasma of thousands of donors and administered via intravenous infusion. The product's approval and sales depend heavily on the immunoglobulin market, regulatory approvals, and healthcare demand.

Market Size and Segments

The global immunoglobulin market, including GAMIMUNE, was valued at approximately $15 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 7-9% through 2030. The growth drivers include rising prevalence of PID, aging populations, and increasing recognition of autoimmune disorders.

Key Market Segments:

• Primary Immunodeficiency: Constitutes 60% of total immunoglobulin sales.
• Autoimmune Diseases: Comprises 30%, including conditions like idiopathic thrombocytopenic purpura (ITP).
• Secondary Immunodeficiency: Accounts for 10%, often caused by chemotherapy or HIV.

Competitive Landscape

GAMIMUNE competes with several brands:

• Gammagard (Takeda)
• Privigen (CSL Behring)
• Flebogamma (Grifols)
• Tegeline (Biotest)

Market share varies regionally, with North America and Europe dominating due to established healthcare infrastructure and reimbursement frameworks.

Market Share (2022 Estimate):

Brand	Global Market Share	Key Markets
Gammagard	28%	US, Europe
Privigen	25%	US, Europe
Flebogamma	20%	Europe, Latin America
GAMIMUNE	15%	US, emerging markets
Others	12%	Global, including Asia-Pacific

Regulatory Environment and Approvals

GAMIMUNE holds approvals from regulatory authorities like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Japanese PMDA. Regulatory considerations impact market access, especially regarding manufacturing standards, plasma collection, and safety protocols.

Manufacturing and Supply Chain

Producers of GAMIMUNE rely on pooled plasma, which necessitates rigorous donor screening, plasma collection, and pathogen inactivation processes. Supply is sensitive to plasma donor availability, donor safety regulations, and geopolitical factors.

Recent supply shortages in 2021-2022 due to plasma donor restrictions have led to procurement issues, affecting sales and pricing dynamics.

Financial Trajectory

Exact sales figures for GAMIMUNE are not publicly disclosed; however, estimates based on market trends suggest:

• 2022 Revenue: Approximately $150 million globally.
• Projected CAGR: 7-8% over 2023-2030.
• 2023-2025 Growth Drivers: Increased demand due to expanded indications, product line extensions, and geographical expansion.
• Pricing Trends: The average price per gram increased 3-5% annually, driven by supply constraints and inflation.

Key Revenue Drivers

• Expansion into Autoimmune and Neuroinflammatory Indications: Increasing off-label and approved uses expand sales.
• New Formulations: High-dose or subcutaneous formulations may boost usage.
• Geographical Expansion: Growth in emerging markets, mainly Asia and Latin America.

Risks and Challenges

• Supply Chain Disruptions: Plasma availability influences production capabilities.
• Pricing Pressures: Healthcare payers seek cost containment, limiting price increases.
• Regulatory Risks: Stringent plasma collection and product approval processes may delay or restrict market access.
• Competition: Market consolidation among large players could affect margins.

Strategic Outlook

Producers of GAMIMUNE are investing in increased plasma collection capacity, process innovation, and expanding indications. Collaborations and licensing agreements are common to access new markets and accelerate growth.

Summary

GAMIMUNE operates within a growing immunoglobulin market driven by increasing clinical needs and demographic trends. Sales growth is moderate, at approximately 7-8% CAGR, constrained by supply chain and pricing pressures. Long-term success depends on supply stability, regulatory navigation, and expanding indications.

Key Takeaways

• The global immunoglobulin market is projected to reach approximately $25 billion by 2030, growing at 7-9% CAGR.
• GAMIMUNE holds around 15% global market share, with revenues approx. $150 million in 2022.
• Supply chain issues and plasma donor availability are significant risks.
• Demand is driven by expanding indications, aging populations, and unmet needs in autoimmune diseases.
• Competition remains intense, with leading brands holding the majority of market share.

FAQs

1. What factors influence GAMIMUNE sales growth?
Demand for immunoglobulin products, supply chain stability, regulatory approvals, and expansion into new indications.

2. How does plasma availability affect GAMIMUNE manufacturing?
Limited donor plasma supplies constrain production capacity, leading to potential shortages and sales impact.

3. What are the key regions for GAMIMUNE?
North America and Europe are current primary markets, with emerging markets showing growth potential.

4. How are pricing dynamics expected to change?
Prices are gradually increasing due to inflation, supply shortages, and high production costs, but are also pressured by payer negotiations.

5. What future developments could impact GAMIMUNE's market?
Innovations in formulation, new therapeutic indications, and regulatory changes impacting plasma collection and product approval.

---

References

[1] MarketsandMarkets. (2023). Immunoglobulin Market by Source, Application, Route of Administration, and Region — Global Forecast to 2030.
[2] IQVIA. (2022). The Immunoglobulin Market Report.
[3] U.S. Food and Drug Administration. (2023). Biologics License Application Approvals.
[4] European Medicines Agency. (2022). Annual Report on Biologics.